Article
Genetics & Heredity
Carina M. Mathey, Carlo Maj, Annika B. Scheer, Julia Fazaal, Bettina Wedi, Dorothea Wieczorek, Philipp M. Amann, Harald Loffler, Lukas Koch, Clemens Schoffl, Heinrich Dickel, Nomun Ganjuur, Thorsten Hornung, Susann Forkel, Jens Greve, Gerda Wurpts, Par Hallberg, Anette Bygum, Christian Von Buchwald, Malgorzata Karawajczyk, Michael Steffens, Julia Stingl, Per Hoffmann, Stefanie Heilmann-Heimbach, Elisabeth Mangold, Kerstin U. Ludwig, Eva R. Rasmussen, Mia Wadelius, Bernhardt Sachs, Markus M. Nothen, Andreas J. Forstner
Summary: This study investigated the possible association between ACEi/ARB-induced angioedema and HAE genes through molecular genetic screening. The results suggest that HAE-associated mutations are, at best, a rare cause of ACEi/ARB-induced angioedema, and there was no significant association found between ACEi/ARB-induced angioedema and other variants in the investigated genes.
FRONTIERS IN GENETICS
(2022)
Article
Medicine, General & Internal
Michael A. Puskarich, Nicholas E. Ingraham, Lisa H. Merck, Brian E. Driver, David A. Wacker, Lauren Page Black, Alan E. Jones, Courtney Fletcher, Andrew M. South, Thomas A. Murray, Christopher Lewandowski, Joseph Farhat, Justin L. Benoit, Michelle H. Biros, Kartik Cherabuddi, Jeffrey G. Chipman, Timothy W. Schacker, Faheem W. Guirgis, Helen T. Voelker, Joseph S. Koopmeiners, Christopher J. Tignanelli
Summary: This study found that oral administration of losartan did not improve the PaO2:FiO(2) ratio at 7 days in hospitalized patients with COVID-19 and acute lung injury. The use of losartan also did not improve secondary clinical outcomes and resulted in fewer vasopressor-free days compared to placebo.
Article
Virology
Sandeep Singh, Christine Widrich, Martijn Nap, Emile Schokker, Aeilko H. Zwinderman, Sara-Joan Pinto-Sietsma
Summary: A global analysis was conducted to explore the association between antihypertensive medications and SARS-CoV-2 severity. The results suggest that ARBs and CCBs may have a protective effect against death from SARS-CoV-2 infection, while ACEis may be associated with a higher mortality rate.
JOURNAL OF MEDICAL VIROLOGY
(2021)
Article
Emergency Medicine
Jennifer E. Lee, Sean M. Bryant
Summary: Angiotensin converting enzyme inhibitor-induced angioedema is typically easily recognizable, but unilateral angioedema is infrequently reported and rare.
AMERICAN JOURNAL OF EMERGENCY MEDICINE
(2021)
Article
Medicine, Research & Experimental
Mauro G. Silva, Gerardo R. Corradi, Juan Perez Duhalde, Myriam Nunez, Eliana M. Cela, Daniel H. Gonzales Maglio, Ana Brizzio, Martin R. Salazar, Walter G. Espeche, Mariela M. Gironacci
Summary: This study found that COVID-19 patients have higher levels of ACE2 expression and enzymatic activity in their blood compared to healthy individuals, while levels of AngII and Ang-(1-7) are lower. Even when excluding COVID-19 patients under RAS blockade treatment, ACE2 expression and enzymatic activity remain higher in COVID-19 patients, suggesting the involvement of RAS in COVID-19.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Review
Cell Biology
Zheng Ma, Mei-Ping Wang, Lian Liu, Shuang Yu, Tian-Ran Wu, Lei Zhao, Ye-Ping Zhang, Hai-Feng Liang, Xin-Chun Yang
Summary: The meta-analysis suggests that the use of ACEI/ARB may increase the risk of COVID-19 infection in the general population, but not in hypertensive individuals. Additionally, ACEI/ARB usage was not associated with adverse outcomes in COVID-19 patients.
Article
Pharmacology & Pharmacy
Shao-Yu Yang, Tao-Min Huang, Tai-Shuan Lai, Nai-Kuan Chou, Chun-Hao Tsao, Yi-Ping Huang, Shuei-Liong Lin, Yung-Ming Chen, Vin-Cent Wu
Summary: The study found that preoperative use of ARBs was associated with a reduced risk of postoperative AKI, especially in high doses, while preoperative use of ACEIs or ARBs was both linked to reduced mortality and did not increase the risk of hyperkalemia.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Medicine, General & Internal
Zhixiang Yu, Dong Zhang, Qiuhe Ji, Fu Yi
Summary: ACEIs/ARBs show good preventive effects on new-onset AF and AF after heart failure. They are particularly effective for preventing secondary AF, especially postoperative AF. However, for patients with hypertension and myocardial infarction, ACEIs/ARBs may not be the best treatment option for preventing AF.
Article
Cardiac & Cardiovascular Systems
Jaejin An, Rong Wei, Hui Zhou, Tiffany Q. Luong, Michael K. Gould, Matthew T. Mefford, Teresa N. Harrison, Beth Creekmur, Ming-Sum Lee, John J. Sim, Jeffrey W. Brettler, John P. Martin, Angeline L. Ong-Su, Kristi Reynolds
Summary: The study found that the use of ACEIs or ARBs was not significantly associated with COVID-19 infection among patients with hypertension. However, there was a lower odds of COVID-19 infection among adults over 85 years old using ACEIs, suggesting that further investigation is warranted.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2021)
Review
Neurosciences
Naif H. Ali, Hayder M. Al-Kuraishy, Ali I. Al-Gareeb, Ali K. Albuhadily, Rabab S. Hamad, Athanasios Alexiou, Marios Papadakis, Hebatallah M. Saad, Gaber El-Saber Batiha
Summary: This article discusses the pathophysiology of depression and the role of the brain renin-angiotensin system (RAS) in it. It is found that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be effective in the treatment of depression. By regulating serotonin, brain-derived neurotrophic factor, mitochondrial dysfunction, oxidative stress, and neuroinflammation, these drugs can ameliorate the pathophysiology of depression.
CNS NEUROSCIENCE & THERAPEUTICS
(2023)
Article
Critical Care Medicine
Genevieve L. Y. Rocheleau, Terry Lee, Yassene Mohammed, David Goodlett, Kevin Burns, Matthew P. Cheng, Karen Tran, David Sweet, John Marshall, Arthur S. Slutsky, Srinivas Murthy, Joel Singer, David M. Patrick, Bin Du, Zhiyong Peng, Todd C. Lee, John H. Boyd, Keith R. Walley, Francois Lamontagne, Robert Fowler, Brent W. Winston, Greg Haljan, Donald C. Vinh, Alison McGeer, David Maslove, Santiago Perez Patrigeon, Puneet Mann, Kathryn Donohoe, Geraldine Hernandez, James A. Russell
Summary: This study examined the effects of angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme (ACE) inhibitors in hospitalized COVID-19 patients, focusing on gender differences. The results showed that ARBs were associated with reduced use of ventilation and vasopressors in male patients, but not in female patients. Additionally, sex-based differences in the renin-angiotensin system (RAS) components may contribute to variations in outcomes and responses to ARBs in COVID-19.
CRITICAL CARE MEDICINE
(2022)
Article
Multidisciplinary Sciences
Ah Ran Oh, Jungchan Park, Jong-Hwan Lee, Jeong Jin Min, Joonhee Gook, Jae Ni Jang, Seung-Hwa Lee, Kyunga Kim, Joonghyun Ahn
Summary: A study on patients undergoing cancer surgery found that RAAS inhibitors had a positive effect in reducing the 5-year mortality and recurrence rates of the patients.
SCIENTIFIC REPORTS
(2022)
Article
Medicine, General & Internal
An-Hsun Chou, Yu-Sheng Lin, Victor Chien-Chia Wu, Fang-Ting Chen, Chia-Hung Yang, Dong-Yi Chen, Shao-Wei Chen
Summary: The study evaluated the effects of beta-blockers, ACEIs, and ARBs in LC patients after cardiac surgery, finding that ARBs were more effective than ACEIs in reducing risks of MACCE, all-cause mortality, liver outcomes, and hepatic encephalopathy.
Article
Cardiac & Cardiovascular Systems
Jianqing She, Bowen Lou, Hui Liu, Bo Zhou, Gulinigaer Tuerhong Jiang, Yongbai Luo, Haoyu Wu, Chen Wang, Zuyi Yuan
Summary: The study revealed that ARNI therapy was more effective than ACEI/ARB therapy in reducing long-term adverse cardiovascular outcomes in patients with AMI. Subgroup analysis indicated that patients with LVEF less than 40% and aged less than 60 years were more likely to benefit from ARNI.
Article
Cardiac & Cardiovascular Systems
Jianqing She, Bowen Lou, Hui Liu, Bo Zhou, Gulinigaer Tuerhong Jiang, Yongbai Luo, Haoyu Wu, Chen Wang, Zuyi Yuan
Summary: This study compared the efficacy of angiotensin receptor-neprilysin inhibitor (ARNI) therapy with angiotensin converting enzyme inhibitor or angiotensin receptor blocker (ACEI/ARB) therapy for cardiovascular outcomes in patients with acute myocardial infarction (AMI). The results showed that ARNI was superior to ACEI/ARB in reducing long-term adverse cardiovascular outcomes, especially for patients with a left ventricular ejection fraction less than 40% and aged less than 60 years.
